NCT05361174 - A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2027

Conditions

Unresectable MelanomaMetastatic MelanomaStage III Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer

Interventions

BIOLOGICAL

IOV-4001

A tumor sample is resected from each participant and cultured ex-vivo to manufacture IOV-4001. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with IOV-4001, and followed by IL-2.

Trial Locations (10)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

32610

RECRUITING

Orlando Health Cancer Institute, Orlando

33136

RECRUITING

Sylvester Comprehensive Cancer Center, Miami

33612

RECRUITING

Moffitt Cancer Center, Tampa

40202

RECRUITING

University of Louisville, Louisville

45219

RECRUITING

University of Cincinnati, Cincinnati

53226

WITHDRAWN

Medical College of Wisconsin, Milwaukee

66205

RECRUITING

The University of Kansas Cancer Center, Westwood

90025

RECRUITING

The Angeles Clinic and Research Institute, Los Angeles